

**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

204427Orig1s000

MEDICAL REVIEW(S)

CLINICAL REVIEW

Application Type NDA
Application Number 204,427
Priority or Standard Standard

Submit Date July 29, 2013
Received Date July 29, 2013
PDUFA Goal Date July 29, 2014
Division / Office DDDP

Reviewer Name Milena Lolic, M.D., M.S.
Review Completion Date March 11, 2014

Established Name Tavaborole solution 5%
Trade Name Kerydin
Therapeutic Class Oxaborole antifungal
Applicant Anacor Pharmaceuticals Inc.

Formulation Solution
Dosing Regimen Daily for 48 weeks
Indication Onychomycosis
Intended Population Adults

Template Version: [March 6, 2009](#)

Table of Contents

1	RECOMMENDATIONS/RISK BENEFIT ASSESSMENT	7
1.1	Recommendation on Regulatory Action	7
1.2	Risk Benefit Assessment.....	7
1.3	Recommendations for Postmarket Risk Evaluation and Mitigation Strategies ...	8
1.4	Recommendations for Postmarket Requirements and Commitments	8
2	INTRODUCTION AND REGULATORY BACKGROUND	9
2.1	Product Information	9
2.2	Currently Available Treatments for Proposed Indication.....	10
2.3	Availability of Proposed Active Ingredient in the United States	12
2.4	Important Safety Issues with Consideration to Related Drugs.....	12
2.5	Summary of Presubmission Regulatory Activity Related to Submission	12
2.6	Other Relevant Background Information	13
3	ETHICS AND GOOD CLINICAL PRACTICES.....	13
3.1	Submission Quality and Integrity.....	13
3.2	Compliance with Good Clinical Practices	13
3.3	Financial Disclosures.....	27
4	SIGNIFICANT EFFICACY/SAFETY ISSUES RELATED TO OTHER REVIEW DISCIPLINES	28
4.1	Chemistry Manufacturing and Controls	28
4.2	Clinical Microbiology.....	29
4.3	Preclinical Pharmacology/Toxicology	33
4.4	Clinical Pharmacology.....	34
4.4.2	Pharmacodynamics.....	35
4.4.3	Pharmacokinetics.....	35
5	SOURCES OF CLINICAL DATA.....	38
5.1	Tables of Studies/Clinical Trials	38
5.2	Review Strategy	39
5.3	Discussion of Individual Studies/Clinical Trials.....	40
6	REVIEW OF EFFICACY	48
	Efficacy Summary.....	48
6.1	Indication.....	49
6.1.1	Methods	49
6.1.2	Demographics.....	50
6.1.3	Subject Disposition	51
6.1.4	Analysis of Primary Endpoint	52
6.1.5	Analysis of Secondary Endpoints(s).....	53
6.1.6	Other Endpoints	55

Clinical Review
Milena Lolic, MD, MS
NDA 204,427
Kerydin (tavaborole) Topical Solution, 5%

6.1.7	Subpopulations	55
6.1.8	Analysis of Clinical Information Relevant to Dosing Recommendations	56
6.1.9	Discussion of Persistence of Efficacy and/or Tolerance Effects.....	56
6.1.10	Additional Efficacy Issues/Analyses	57
7	REVIEW OF SAFETY.....	59
	Safety Summary	59
7.1	Methods.....	60
7.1.1	Studies/Clinical Trials Used to Evaluate Safety	60
7.1.2	Categorization of Adverse Events.....	63
7.1.3	Pooling of Data Across Studies/Clinical Trials to Estimate and Compare Incidence.....	63
7.2	Adequacy of Safety Assessments	63
7.2.1	Overall Exposure at Appropriate Doses/Durations and Demographics of Target Populations	63
7.2.2	Explorations for Dose Response.....	65
	Study AN2690-ONYC-200/200A	68
7.2.3	Special Animal and/or In Vitro Testing	70
7.2.4	Routine Clinical Testing	70
7.2.5	Metabolic, Clearance, and Interaction Workup	71
7.2.6	Evaluation for Potential Adverse Events for Similar Drugs in Drug Class ..	71
7.3	Major Safety Results	71
7.3.1	Deaths.....	71
7.3.2	Nonfatal Serious Adverse Events	72
7.3.3	Dropouts and/or Discontinuations	75
7.3.4	Significant Adverse Events	77
7.3.5	Submission Specific Primary Safety Concerns	78
7.4	Supportive Safety Results	80
7.4.1	Common Adverse Events	80
7.4.2	Laboratory Findings	82
7.4.3	Vital Signs.....	83
7.4.4	Electrocardiograms (ECGs)	83
7.4.5	Special Safety Studies/Clinical Trials.....	84
7.4.6	Immunogenicity.....	87
7.5	Other Safety Explorations.....	87
7.5.1	Dose Dependency for Adverse Events	87
7.5.2	Time Dependency for Adverse Events.....	88
7.5.3	Drug-Demographic Interactions	89
7.5.4	Drug-Disease Interactions.....	91
7.5.5	Drug-Drug Interactions.....	91
7.6	Additional Safety Evaluations	92
7.6.1	Human Carcinogenicity	92
7.6.2	Human Reproduction and Pregnancy Data.....	92
7.6.3	Pediatrics and Assessment of Effects on Growth	93

Clinical Review
Milena Lolic, MD, MS
NDA 204,427
Kerydin (tavaborole) Topical Solution, 5%

7.6.4	Overdose, Drug Abuse Potential, Withdrawal and Rebound.....	95
7.7	Additional Submissions / Safety Issues	95
8	POSTMARKET EXPERIENCE.....	95
9	APPENDICES	96
9.1	Literature Review/References	96
9.2	Labeling Recommendations	96
9.3	Advisory Committee Meeting.....	96
9.4.	Clinical Investigator Financial Disclosure	96

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.